Stephen M Hanson

US Patent:

50342657, Jul 23, 1991

Filed:

Aug 21, 1989

Appl. No.:

7/398312

Inventors:

Allan S. Hoffman - Seattle WA
Andrew M. Garfinkle - Montreal, CA
Buddy D. Ratner - Seattle WA
Stephen R. Hanson - Encinitas CA

Assignee:

Washington Research Foundation - Seattle WA

International Classification:

B32B 2700
A01N 102
B05D 306
A61M 2500

US Classification:

428253

Abstract:

A method of treating articles to improve their biocompatibility is disclosed. A polymeric substrate material is positioned within a reactor vessel and exposed to plasma gas discharge in the presence of an atmosphere of an inert gas and then in the presence of an organic gas, such as a fluorinated hydrocarbon gas, which forms a thin, biocompatible surface covalently bonded to the surface of the substrate. The method is particularly useful in the treatment of vascular graft materials to produce grafts that are both thrombi- and emboli-resistant.

US Patent:

20200397981, Dec 24, 2020

Filed:

Jun 18, 2020

Appl. No.:

16/905176

Inventors:

- Melbourne FL, US
Stephen R. HANSON - Edmonds WA, US

International Classification:

A61M 5/145
A61M 5/142
A61M 5/168
A61M 5/148

Abstract:

Refillable compression-activated pump devices having a first reservoir, a second reservoir connected by a one-way valve and methods of using the pump devices are provided. The compression-activated pumps can be filled with fluid containing a drug, pressurized by compressing the first or second reservoir to deliver the drug to another device, and refilled when drug is depleted.

US Patent:

20190308000, Oct 10, 2019

Filed:

Apr 3, 2019

Appl. No.:

16/373977

Inventors:

- Melbourne FL, US
Stephen R. HANSON - Edmonds WA, US

International Classification:

A61M 31/00
A61M 5/142
A61F 2/06

Abstract:

Dual-lumen devices for delivery of drugs to a drug reservoir, blood vessel or vascular graft and methods of using the same are provided. In one aspect, devices comprising a dual-lumen needle and dual-lumen catheter are provided for filling and removing drug formulations from a drug reservoir are provided. The drug reservoir can optionally be connected to or associated with a vascular graft or blood vessel for controlled delivery of the drug.

US Patent:

20180355057, Dec 13, 2018

Filed:

Jul 30, 2018

Appl. No.:

16/049141

Inventors:

- Portland OR, US
- Nashville TN, US
Stephen Raymond Hanson - Edmonds WA, US
David Gailani - Franklin TN, US

Assignee:

Oregon Health & Science University - Portland OR
Vanderbilt University - Nashville TN

International Classification:

C07K 16/36
A61K 45/06
A61K 39/395
A61K 39/00

Abstract:

Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the disclosure include administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction.

US Patent:

20180153810, Jun 7, 2018

Filed:

Jul 12, 2017

Appl. No.:

15/647919

Inventors:

- San Diego CA, US
Alison J. PILGRIM - Castillon-Du-Gard, FR
Stephen R. HANSON - Edmonds WA, US

International Classification:

A61K 9/16
A61K 31/519
A61K 9/48
A61K 9/00
A61K 9/20

Abstract:

Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

US Patent:

20170252447, Sep 7, 2017

Filed:

Mar 1, 2017

Appl. No.:

15/447073

Inventors:

- Melbourne FL, US
Stephen R. Hanson - Edmonds WA, US
Christopher F. Toombs - Sammamish WA, US

International Classification:

A61K 47/26
A61K 9/00
A61K 31/436
A61K 47/10
A61K 9/08

Abstract:

A novel treatment for dialysis patients needing a hemodialysis graft by providing a therapeutic formulation that can be infused to such patients, which may mitigate graft-related neointimal hyperplasia, thrombosis, and/or related mechanisms of graft failure. The therapeutic formulation may include sirolimus and/or other olimus drug(s). The therapeutic formulation may be infusible and stable in solution for such a pharmaceutical and therapeutic purpose. The therapeutic formulation may have a pharmaceutically acceptable shelf life such that the pharmaceutical agent remains chemically stable (e.g., does not precipitate) for a suitable number of days (e.g., at least 30 days, at least 60 days, at least 90 days, etc.) at 37 C. The therapeutic formulation may be suitable for application to a patient's blood vessel/vascular graft via an infusion pump. For instance, the therapeutic formulation may be suitable for application to the patient's hemodialysis graft location.

US Patent:

20170204195, Jul 20, 2017

Filed:

Mar 27, 2017

Appl. No.:

15/470758

Inventors:

- Portland OR, US
- Nashville TN, US
Stephen Raymond Hanson - Edmonds WA, US
David Gailani - Franklin TN, US

Assignee:

Oregon Health & Science University - Portland OR
Vanderbilt University - Nashville TN

International Classification:

C07K 16/36

Abstract:

Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the disclosure include administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction.

US Patent:

20170112767, Apr 27, 2017

Filed:

May 31, 2016

Appl. No.:

15/169345

Inventors:

- San Diego CA, US
Alison J. PILGRIM - Castillon-Du-Gard, FR
Stephen R. HANSON - Edmonds WA, US

International Classification:

A61K 9/16
A61K 9/48
A61K 31/519
A61K 9/20
A61K 9/00

Abstract:

Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.